Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.13
    -0.94 (-5.85%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sarepta Therapeutics Inc (SRPT) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Sarepta Therapeutics (SRPT) to earn $3.95 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.86B. Of 24 analysts, 7 rate the stock Buy or Strong Buy, 12 Hold and 5 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 3.00, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 29% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy729.2%
    Hold1250.0%
    Sell312.5%
    Strong Sell28.3%
    Consensus
    Hold
    Total analysts
    24

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus falls 62.5% and revenue estimates fall 25.8%.

    Fiscal year ending Dec 31, 2026
    $3.95
    EPS consensus, revenue $1.86B
    Fiscal year ending Dec 31, 2027
    $1.48
    EPS consensus, revenue $1.38B
    Next report
    Feb 23, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.95$2.05 to $5.0311$1.86B$1.80B to $1.89B20
    Dec 31, 2027$1.48-$0.30 to $3.4711$1.38B$856.94M to $1.79B20

    Quarterly Estimates

    The EPS consensus rises from -$0.37 for the quarter ending Dec 31, 2026 to $0.44 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.37-$1.53 to $0.2124$360.44M$294.75M to $400.47M22
    Mar 31, 2027$0.44-$0.02 to $0.966$357.09M$320.70M to $383.90M11

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 6 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202603
    Fiscal year ending Dec 31, 202712
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 10.0% from $4.39.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.95$4.32$4.32$4.44$4.39-9.9%
    Fiscal year ending Dec 31, 2027$1.48$2.45$2.41$2.57$2.60-42.9%
    Quarter ending Mar 31, 2027$0.44$0.73$0.78$0.75$0.78-43.9%

    Frequently Asked Questions About SRPT

    What is the SRPT stock forecast?

    Consensus analyst estimates put Sarepta Therapeutics's EPS at $3.95 for the fiscal year ending Dec 31, 2026, on revenue of $1.86B. The consensus rating from 24 analysts is Hold.

    How do analysts rate SRPT stock?

    Of 24 analysts covering Sarepta Therapeutics, 0 rate it Strong Buy, 7 Buy, 12 Hold, 3 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from SRPT next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.95, with estimates from $2.05 to $5.03 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.48, with estimates from -$0.30 to $3.47 from 11 analysts.

    What revenue do analysts expect from Sarepta Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.86B, with estimates from $1.80B to $1.89B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.38B, with estimates from $856.94M to $1.79B.

    How many analysts cover SRPT?

    24 analysts rate Sarepta Therapeutics stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.